GM-CSF for Osteosarcoma

Phase-Based Progress Estimates
MD ANDERSON CANCER CENTER (Data Collection Only), Houston, TXOsteosarcomaGM-CSF - Drug
13 - 40
All Sexes
What conditions do you have?

Study Summary

This trial is testing an antibody and drug combo to see if it can keep cancer in remission or prevent it from coming back.

Eligible Conditions
  • Osteosarcoma

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 12 months

12 months
event free survival (EFS)
time to recurrence

Trial Safety

Trial Design

1 Treatment Group

humanized anti-GD2 antibody, hu3F8, when combined with GM-CSF
1 of 1

Experimental Treatment

46 Total Participants · 1 Treatment Group

Primary Treatment: GM-CSF · No Placebo Group · Phase 2

humanized anti-GD2 antibody, hu3F8, when combined with GM-CSFExperimental Group · 2 Interventions: GM-CSF, humanized anti-GD2 antibody · Intervention Types: Drug, Biological
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months

Who is running the clinical trial?

Y-mAbs TherapeuticsIndustry Sponsor
24 Previous Clinical Trials
1,492 Total Patients Enrolled
1 Trials studying Osteosarcoma
11 Patients Enrolled for Osteosarcoma
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,845 Previous Clinical Trials
589,969 Total Patients Enrolled
10 Trials studying Osteosarcoma
1,031 Patients Enrolled for Osteosarcoma
Children's Hospital Los AngelesOTHER
207 Previous Clinical Trials
5,071,701 Total Patients Enrolled
2 Trials studying Osteosarcoma
110 Patients Enrolled for Osteosarcoma
M.D. Anderson Cancer CenterOTHER
2,824 Previous Clinical Trials
1,792,492 Total Patients Enrolled
14 Trials studying Osteosarcoma
526 Patients Enrolled for Osteosarcoma
Filemon Dela Cruz, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Eligibility Criteria

Age 13 - 40 · All Participants · 14 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You should not have difficulty breathing or experience shortness of breath while resting or during exercise.

Frequently Asked Questions

Is this investigation a groundbreaking case of its kind?

"GM-CSF has been extensively researched, with the first trials sponsored by Y-mAbs Therapeutics in 2011. Following successful Phase 1 clinical testing involving 68 patients, several live studies have since followed across 8 cities and 9 countries." - Anonymous Online Contributor

Unverified Answer

Does this experiment admit geriatric individuals?

"According to the enrollment requirements, patients must be between 13 months and 40 years old. Meanwhile, there are 233 studies available for minors while 958 clinical trials pertain to seniors 65 or older." - Anonymous Online Contributor

Unverified Answer

How many subjects have been enrolled in this clinical experiment?

"Affirmative. documents show that this medical study, initially posted on the 1st of July 2015, is recruiting patients currently. This clinical trial aims to enlist 46 individuals from 3 different sites." - Anonymous Online Contributor

Unverified Answer

Is there still an opportunity to join this experiment?

"Based on the data available from, this medical study is presently enrolling patients. The trial was made public on July 1st 2015, and its details were last updated in November 17th 2022." - Anonymous Online Contributor

Unverified Answer

What research has been conducted in relation to the use of GM-CSF?

"The initial investigation of GM-CSF took place in 2011 at Memorial Sloan Kettering Cancer Center. Thus far, 41 studies have been concluded with 7 trials ongoing as of now; many of these are hosted by medical centres situated in Houston, Texas." - Anonymous Online Contributor

Unverified Answer

What potential risks does GM-CSF pose to those who utilize it?

"This Phase 2 trial has evidence to suggest that GM-CSF is safe, resulting in an estimated score of 2 on our Power scale. Unfortunately, there is not yet any data supporting its efficacy." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.